Ariceum Therapeutics

Berlin, Germany Founded: 2021 • Age: 5 yrs
Developer of drugs for systemic targeted radiation therapy to treat cancer
Request Access

About Ariceum Therapeutics

Ariceum Therapeutics is a company based in Berlin (Germany) founded in 2021.. Ariceum Therapeutics has raised $51.64 million across 2 funding rounds from investors including EQT, Andera Partners and Earlybird. Ariceum Therapeutics has completed 1 acquisition, including Theragnostics. Ariceum Therapeutics offers products and services including NephroScan. Ariceum Therapeutics operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Lantheus, among others.

  • Headquarter Berlin, Germany
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Ariceum Therapeutics Gmbh
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $51.64 M (USD)

    in 2 rounds

  • Latest Funding Round
    $24.92 M (USD), Series A

    Apr 18, 2023

  • Investors
    EQT

    & 4 more

  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Ariceum Therapeutics

Ariceum Therapeutics offers a comprehensive portfolio of products and services, including NephroScan. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Radiopharmaceutical for visualizing and treating cancer through targeted therapy.

People of Ariceum Therapeutics
Headcount 10-50
Employee Profiles 5
Employee Profiles
People
Manfred Ruediger
CEO of Ariceum Therapeutics GmbH
People
Germo Gericke
Chief Medical Officer
People
Manuel Sturzbecher-Hoehne
Chief Technology Officer, CTO
People
Aaron Block, MBA
Senior Director Business Development

Unlock access to complete

Funding Insights of Ariceum Therapeutics

Ariceum Therapeutics has successfully raised a total of $51.64M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $24.92 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $24.9M
  • First Round

    (08 Jun 2022)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2023 Amount Series A - Ariceum Therapeutics Valuation Andera Partners , Earlybird
Jun, 2022 Amount Series A - Ariceum Therapeutics Valuation Healthcap
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Ariceum Therapeutics

Ariceum Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include EQT, Andera Partners and Earlybird. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Capital is provided to firms for growth, buyouts, and acquisitions.
Founded Year Domain Location
Earlybird is recognized as a venture capital investor focused on early-stage tech companies.
Founded Year Domain Location
Venture capital is invested in innovative drug development companies.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Ariceum Therapeutics

Ariceum Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Theragnostics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Gallium-based diagnostic and therapeutic agents are developed and commercialized.
2015
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Ariceum Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Ariceum Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Ariceum Therapeutics

Ariceum Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Lantheus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Developer of molecular imaging systems and radio-pharmaceuticals
domain founded_year HQ Location
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
domain founded_year HQ Location
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
domain founded_year HQ Location
Developer of diagnostic imaging agents and targeted therapeutics
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Ariceum Therapeutics

Frequently Asked Questions about Ariceum Therapeutics

When was Ariceum Therapeutics founded?

Ariceum Therapeutics was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Ariceum Therapeutics located?

Ariceum Therapeutics is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.

Who is the current CEO of Ariceum Therapeutics?

Manfred Ruediger is the current CEO of Ariceum Therapeutics.

Is Ariceum Therapeutics a funded company?

Ariceum Therapeutics is a funded company, having raised a total of $51.64M across 2 funding rounds to date. The company's 1st funding round was a Series A of $26.72M, raised on Jun 08, 2022.

What does Ariceum Therapeutics do?

Developer of drugs for systemic targeted radiation therapy to treat cancer. The lead radiopharmaceutical product, satoreotide is an antagonist of the somatostatin type 2 (SST2) receptor. It is used for the treatment of neuroendocrine cancers, small cell lung cancer, and neuroblastoma.

Who are the top competitors of Ariceum Therapeutics?

Ariceum Therapeutics's top competitors include Advanced Accelerator Applications, SOFIE and AdvanCell.

What products or services does Ariceum Therapeutics offer?

Ariceum Therapeutics offers NephroScan.

How many acquisitions has Ariceum Therapeutics made?

Ariceum Therapeutics has made 1 acquisition, including Theragnostics.

Who are Ariceum Therapeutics's investors?

Ariceum Therapeutics has 5 investors. Key investors include EQT, Andera Partners, Earlybird, Pureos Bioventures, and Healthcap.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available